Sleep apnea is a serious condition that has long been associated with an increased risk of cardiovascular events and mortality. However, new research presented at the European Congress on Obesity (ECO 2026) has revealed just how significant this risk is. The study, conducted by Imperial College Health Partners and Eli Lilly and Company, found that individuals with obstructive sleep apnea (OSA) have a 71% higher risk of experiencing cardiovascular events or death from any cause compared to those without OSA. This finding highlights the critical need for effective obesity management and emphasizes the importance of early screening and timely diagnosis. What makes this study particularly compelling is its large sample size, drawing from the health records of 2.9 million residents in North-West London, UK. This extensive data set allows for a more comprehensive understanding of the relationship between OSA and cardiovascular risk, especially among those with obesity. The study's primary objective was to assess the increased risk of cardiovascular events or death among adults with OSA compared to those without. Secondary objectives included evaluating the risk of key comorbidities such as diabetes, osteoarthritis, and comparing healthcare resource utilization (HCRU) between the two groups. The results were striking. People with OSA had a 71% higher risk of CVEs or all-cause mortality compared to their matched controls without OSA. Within four years of the index date, 26.3% of those with OSA experienced CVEs or all-cause mortality, compared to 17.5% of matched controls. This higher risk was even more pronounced among those with obesity, who are more likely to experience severe OSA. The study also revealed that individuals with OSA had higher proportions of developing obesity, diabetes, osteoarthritis, anxiety, and depression compared to those without OSA. Furthermore, people with OSA had higher healthcare resource utilization, with more primary care visits, outpatient attendances, and inpatient days compared to their matched controls. These findings underscore the need for effective obesity management and highlight the importance of early screening and timely diagnosis. The study's large sample size and comprehensive analysis make it a significant contribution to the field of sleep apnea research. It provides valuable insights into the relationship between OSA and cardiovascular risk, especially among those with obesity. As Heather Fitzke, a co-author of the study, noted, this is the largest matched case-control study of obstructive sleep apnea outside the U.S. to date. The findings emphasize the importance of recognizing and treating OSA to reduce the risk of cardiovascular events and mortality. In my opinion, this study highlights the critical need for healthcare providers to be vigilant in identifying and managing OSA, especially in individuals with obesity. Early intervention can significantly reduce the risk of cardiovascular events and improve overall health outcomes. Additionally, the study's findings underscore the importance of public health initiatives aimed at raising awareness about OSA and promoting healthy lifestyle choices. By addressing obesity and other risk factors, we can help reduce the burden of OSA and improve the health of our communities. In conclusion, this research highlights the significant impact of sleep apnea on cardiovascular health, especially among those with obesity. It emphasizes the need for effective obesity management and early screening and diagnosis. As healthcare providers and policymakers, we must take action to address this critical public health issue and improve the health outcomes of those affected by OSA.
